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Abstract
The present study examined the impact of implant surface 
modifications on osseointegration in an osteoporotic rodent 
model. Sandblasted, acid-etched titanium implants were 
either used directly (control) or were further modified by 
surface conditioning with NaOH or by coating with one of 
the following active agents: collagen/chondroitin sulphate, 
simvastatin, or zoledronic acid. Control and modified 
implants were inserted into the proximal tibia of aged 
ovariectomised (OVX) osteoporotic rats (n = 32/group). 
In addition, aged oestrogen competent animals received 
either control or NaOH conditioned implants. Animals were 
sacrificed 2 and 4 weeks post-implantation. The excised tibiae 
were utilised for biomechanical and morphometric readouts 
(n = 8/group/readout). Biomechanical testing revealed at 
both time points dramatically reduced osseointegration 
in the tibia of oestrogen deprived osteoporotic animals 
compared to intact controls irrespective of NaOH exposure. 
Consistently, histomorphometric and microCT analyses 
demonstrated diminished bone-implant contact (BIC), peri-
implant bone area (BA), bone volume/tissue volume (BV/
TV) and bone-mineral density (BMD) in OVX animals. 
Surface coating with collagen/chondroitin sulphate had no 
detectable impact on osseointegration. Interestingly, statin 
coating resulted in a transient increase in BIC 2 weeks 
post-implantation; which, however, did not correspond to 
improvement of biomechanical readouts. Local exposure 
to zoledronic acid increased BIC, BA, BV/TV and BMD 
at 4 weeks. Yet this translated only into a non-significant 
improvement of biomechanical properties. In conclusion, 
this study presents a rodent model mimicking severely 
osteoporotic bone. Contrary to the other bioactive agents, 
locally released zoledronic acid had a positive impact on 
osseointegration albeit to a lesser extent than reported in 
less challenging models.
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Introduction
Subsequent to placement of an implant into bone, the 
osseous wound undergoes sequentially haemostasis, 
inflammation and proliferation analogous to the phases 
of fracture healing (Schindeler et al., 2008). Primary 
implant stability is enabled by an interlock between an 
implant and the host bone. During osseous healing, host 
bone in proximity to the implant will be resorbed and new 
woven bone will be formed (Davies, 1998). This leads to 
a transient decrease in stability until secondary implant 
stability is established. Remodelling processes around 
the implant will continue for an extended time period 
depending on species, loading of the implant, and bony 
template (Branemark et al., 1977).
 The implant surface structure and composition has 
an impact on the attachment of proteins and subsequent 
cellular processes, which are relevant to implant 
osseointegration (Junker et al., 2009). Ideally, an implant 
should be characterised by high primary stability and 
a sufficient and persistent degree of osseointegration 
(Esposito et al., 1998; Sennerby and Meredith, 2008; 
Martin et al., 2009). In recent years, several techniques 
of surface modification emerged in order to stimulate 
peri-implant bone formation and thus osseointegration. 
It was demonstrated, that roughened surfaces positively 
influence biomechanical anchorage and bone formation 
(Butz et al., 2006). Moreover, surface conditioned 
implants showed increased rates of bone formation (Buser 
et al., 2004; Stadlinger et al., 2009b). Another approach, 
which is increasingly explored, is the coating of implant 
surfaces with components of the bone extracellular matrix 
in order to influence mediators involved in early phases 
of osseointegration (Rammelt et al., 2007; Stadlinger et 
al., 2009a). Such surface coatings have been shown to 
increase bone formation in comparison to sandblasted, 
acid-etched implants in uncompromised host bone 
(Stadlinger et al., 2009a). From the clinical point of view, 
stimulation of osseointegration is of particular interest 
in compromised bone. Osteoporosis, characterised by 
low bone mass and increased bone fragility, is a skeletal 
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disorder that represents such a compromised setting. The 
correlation between systemic bone and oral bone loss has 
been demonstrated (Jeffcoat, 2005; Wactawski-Wende 
et al., 2005), a correlation to implant loss, however, 
has not been found (Holahan et al., 2008). A common 
therapy for osteoporotic patients is the application of 
drugs that inhibit bone resorption and thus further bone 
loss. Bisphosphonates represent the largest group of these 
anti-resorptive drugs currently in clinical use (Rachner 
et al., 2011). Accordingly, coating of implant surfaces 
with bisphosphonates has been explored for its ability to 
improve implant osseointegration and testing in animal 
studies yielded positive results (Wermelin et al., 2007; 
Wermelin et al., 2008a). Another approach is to improve 
osseointegration by stimulation of bone formation. This has 
been explored utilising statin coated implants (Moriyama 
et al., 2010), based on the finding that statins induce bone 
morphogenetic protein-2 (BMP-2) expression and promote 
osteoblastic BMP signalling (Mundy et al., 1999), which 
is critical during osseointegration and fracture healing. 
Also for this approach positive findings were reported in 
a pre-clinical animal model (Du et al., 2009).
 In the present study we analysed biochemically modified 
implants in a severely compromised setting. Implants were 
inserted into the proximal tibia of oestrogen deprived rats 
with established osteoporosis. The aim of the study was 
to test whether these biochemical modifications that have 
been reported previously to enhance osseointegration in 
healthy bone would yield a similar effect in osteoporotic 
bone.
Materials and Methods
Animals
The experimental protocol of this study and animal care 
conformed to the Swiss federal law for animal protection 
under the control of the Basel-Stadt Cantonal Veterinary 
Office, Switzerland. Hundred and sixty, six-month old 
female virgin Wistar rats underwent bilateral ovariectomy 
(OVX), while another 64 rats underwent sham surgery and 
remained intact. Fourteen weeks post-surgery the animals 
were divided into five OVX- and two non-OVX groups 
(32 rats/group) with an even distribution of proximal tibial 
bone-mineral density as assessed by microCT and body 
weight within the OVX groups and the intact groups. Each 
of the seven groups was randomly divided into two sub-
groups (16 rats/sub-group), designated to 2 and 4 weeks of 
implant healing. The animals received one implant in the 
left proximal tibia metaphysis. Tibial bone samples from 
eight animals per sub-group were assessed by microCT 
and histomorphometry; the additional eight samples were 
utilised for biomechanical testing.
Implants
Experimental threaded titanium implants (grade 4) with an 
inner diameter of 1.1 mm, outer diameter of 1.7 mm and 
a length of 3.0 mm (Thommen Medical AG, Waldenburg, 
Switzerland) received different surface treatments. 
Implants had a cuboid implant head in order to allow 
biomechanical testing. The surface of all implants had been 
sandblasted and thermally acid-etched (SAE). The Sa value 
of this procedure is approximately 2.0 µm (Stadlinger et al., 
2012). Sixty-four implants were conditioned by a solution 
containing hydroxide ions prior to implant placement as 
described previously (Stadlinger et al., 2012). Thirty-two 
implants were coated in a solution of 1 mg/mL collagen 
type I and chondroitin sulphate at a concentration of 50 µg/
mL, as described previously (Stadlinger et al., 2009a). 
Another 32 implants were coated with a simvastatin-
chitosan complex using a modified spin coating procedure. 
A homogeneous suspension of 57 µg simvastatin complex 
in 5 µL acetone containing 35 µg simvastatin per implant 
has been used. The implants were fixed in a horizontally 
positioned stirring motor (Eurostar Digital, IKA–Werke, 
Staufen, Germany) rotating at a constant speed of 
300 rpm. The simvastatin suspension was dropped into the 
implant thread turns using a precision pipette (Eppendorf 
Reseach, Hamburg, Germany; 0.5-10 µL volume), which 
was positioned at a distance of 1-2 mm over the rotating 
implant. Implant rotation results in a homogeneous 
distribution of the coating within the implant thread.
 Finally, 32 implants were coated with a zoledronic 
acid–stearate complex using the method described above. 
A homogeneous suspension of 23.8 µg of zoledronic-acid-
stearate complex in acetone containing 8.5 µg zoledronic 
acid per implant was used. After coating, both simvastatin 
and zoledronate-containing implants were stored for 
30 min at 60 °C to remove the solvent. All implants were 
sterilised by gamma-radiation.
 In vitro release studies have been performed measuring 
the amount of released simvastatin and zoledronic acid, 
respectively, within a time period of 14 days. For this 
purpose titanium discs (grade 4, 15 mm in diameter, 
surface treated in the same way as the implants) coated 
with the simvastatin-chitosan and the zoledronic acid-
stearate complex, respectively, were stored into simulated 
body fluid (SBF) medium (simvastatin-coated discs) and, 
physiological NaCl solution (zoledronic acid-coated 
discs) respectively, and the released amount of bioactive 
agent after 1, 2, 3, 5, 7 and 14 days was measured. The 
amount of released simvastatin and zoledronic acid was 
quantified by UV/Vis spectroscopy. For zoledronic acid 
quantification the spectrophotometric method reported by 
Gallez et al. (1988) was employed. All experiments were 
run in duplicates. Release data are shown in Table 1.
Implant procedure
Animals were anaesthetised with ketamine and xylazine 
by intraperitoneal injection and received buprenorphine 
for analgesic purposes. All operative procedures were 
performed under sterile conditions. For implant placement, 
a 15 mm longitudinal incision was made along the medial 
side of the tibia and a musculoperiosteal flap was elevated. 
A conical drill with a diameter of 1.1-1.5 mm in diameter 
was used to generate, under water cooling, an osteotomy 
2 mm distal to the growth plate of the proximal left tibia. 
Implants were placed using an implant screwdriver. 
After placement, a rounded polyether ether ketone 
healing-cap was placed on the cuboid implant top. The 
soft tissue was repositioned and sutured in two layers, 
using resorbable sutures (Safil 6x0, Braun, Melsungen, 
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Germany). An aerosol bandage was applied (Flint MED, 
Togal-Werk AG, München, Germany) and wound healing 
was controlled daily for the first week and twice per week 
during the following healing periods. All animals received 
fluorochrome markers by subcutaneous injection 10 days 
(alizarin complexone, 20 mg/kg; Merck, Zug, Switzerland) 
and 3 days (calcein, 30 mg/kg, Sigma-Aldrich, Steinheim, 
Germany) prior to sacrifice.
Tissue processing
After sacrifice, the left tibiae were harvested. The proximal 
halves were fixed in Schaffer`s solution for 24 h at 4 °C, 
followed by 70 % ethanol. Following ex vivo microCT 
analysis, the samples were dehydrated and embedded in 
methylmethacrylate to generate 50 µm ground sections cut 
in parallel to the implant length axis and perpendicular to 
the tibial axis as described previously (Donath and Breuner, 
1982). Fluorescent microscopy was performed prior to 
Masson-Goldner staining.
Computed tomography
For even distribution of animals into groups prior to 
implant surgery, cross-sectional apparent cancellous 
bone-mineral density (BMD) was evaluated in the left 
proximal tibia metaphysis by peripheral quantitative 
computed tomography (pQCT, Norland XCT-2000 Stratec, 
Pforzheim, Germany, fitted with an Oxford 50 AM X-ray 
tube and a collimator of 1 mm diameter; voxel size: 0.2 x 
0.2 x 1 mm; scan speed: scout view 20 mm/s; final scan 
10 mm/s, 1 block, contour mode 1, peel mode 2; threshold: 
610 mg/cm3).
 Ex vivo CT measurements were performed with a 
microCT40 (Scanco Medical, Brüttisellen, Switzerland; 
voxel size, 10 µm; high resolution; 192 slices, energy, 
70 E(kVp), 114 µA, high resolution, integration time 
300 ms, conebeam continuous rotation) as previously 
described (Rebaudi et al., 2004). Briefly, bone and titanium 
implant were distinguished using the appropriate Gaussian 
filters (sigma 1.2 bone, 2.0 titanium; support 2 bone, 
Table 1. In vitro release of simvastatine and zoledronic acid.
Complex
Cumulative amount of released agent [%]
Release time [d]
1 2 3 5 7 14
Simvastatin-
chitosan 20.4 ± 2.8 22.3 ± 3.1 22.7 ± 3.1 22.9 ± 3.1 23.1 ± 3.1 23.2 ± 3.1
Zoledronic acid-
stearate 34.2 ± 2.8 49.5 ± 5.5 62.9 ± 6.1 69.5 ± 6.2 71.1 ± 4.7 71.1 ± 4.7
Table 2. Results of microcomputed tomography at two and four weeks (µCT).
Group Surface
Healing time BIC cancellous bone BV/TV 200 μm BMD 200 μm
[weeks] n [%] SD n [%] SD  n [mgHA/ccm] SD
non- 
OVX
reference 2 7 68.6# 10.8 7 48.6# 13.3 7 883.9# 107.5
reference 4 7 67.7# 13.9 7 50.5# 17.1 7 891.3# 152.3
conditioned 2 6 69.5# 14.9 7 50.7# 15.7 7 891.0# 140.5
conditioned 4 6 62.1# 13.7 7 46.6# 17.9 7 861.4# 161.7
OVX
reference 2 6 31.3* 11.9 7 10.8*  5.7 7 491.2* 105.8
reference 4 6 20.6*  2.4 7  4.7*  3.5 7 361.6*   62.6
conditioned 2 6 30.2* 10.7 7 11.8*  5.1 8 470.7*   89.6
conditioned 4 7 25.4*  4.5 7  6.4*  2.4 7 404.5*   38.6
collagen/CS 2 8 36.3*  6.7 8 12.6*  4.3 8 503.9*   72.8
collagen/CS 4 7 21.4*  3.8 7  3.8*  1.7 7 355.8*   24.8
simvastatin 2 6 50.8#  6.6 7 19.3*  6.4 7 592.7*   81.5
simavstatin 4 6 35.6* 10.7 7 10.5*  5.4 7 453.9*   83.9
zoledronic 
acid 2 6 31.8*  8.4 7 15.1*  8.8 7 532.5* 125.7
zoledronic 
acid 4 8  47.8*# 10.4 8  23.0*# 11.3 8 602.1*# 128.0
Significantly different (p ≤ 0.05) compared to reference in non- OVX (*) or OVX (#) rats at the same time point.
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Fig, 1. Regions of interest for (a) micro-CT measurements and (b) histomorphometric measurements.
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3 titanium) and threshold procedures (bone: 370-700; 
titanium implant 700-1000). BMD and bone volume/tissue 
volume (BV/TV) were determined in the cancellous bone 
region surrounding the implant (3 to 10 voxels distance 
from the implant) and in a neighbouring region in further 
distance to the implant surface (10 to 23 voxels distance 
from the implant) (Fig. 1a). Since results did not differ 
between the two regions, data were merged for the results 
presented in Table 2 and reflect a total width of 200 µm. 
In addition, bone-implant contact (BIC) was determined. 
In order to avoid artefacts due to the titanium implant, BIC 
measurements were performed at a distance of 30 µm (i.e., 
3 voxels) from the surface. The number of surface voxels 
attached to bone at this distance divided by the total number 
of implant surface voxels was used to derive the BIC in 
percentage, as described by Rebaudi et al. (2004).
Histomorphometry
Fluorescence microscopy was performed at up to 40x 
magnification (Olympus BX 61, Hamburg, Germany). 
Polyfluorochrome labels were qualitatively analysed 
for bone growth dynamics, location and label sequence. 
Subsequently stained sections were imaged using a 
motorised measuring stage (Märzhäuser, Wetzlar, 
Germany) for multiple alignment scanning connected 
to a computerised system of histomorphometry (CellˆF, 
Imaging Software for Life Science, Olympus). BIC was 
measured in the cancellous bone compartment along 
the implant surface. The apex of the implant was not 
included. Cancellous bone area per tissue area (BA/TA) 
was measured in a region adjacent to the implant and in a 
surrounding distant area (Fig. 1b).
Biomechanical evaluation
All specimens underwent biomechanical testing at the day 
of harvest. Healing caps were removed and the tibiae were 
embedded in dental plaster (Fujirock EP, Improved type 
4 dental stone, GC Europe, Kortrijk, Belgium), using a 
custom potting device which provides coaxial alignment 
of the implant and the testing machine. Specimens were 
mounted on a servohydraulic testing machine (MTS 858 
Mini Bionix, MTS Systems, Eden Prairie, MN, USA) and 
connected to a 2 Nm load cell/signal amplifier (D2209, 
Lorenz Messtechnik, Alfdorf, Germany, accuracy 2 Nmm). 
A mechanical flex clutch was used to ensure neutral initial 
fixation (no moment). Implants were rotated counter-
clockwise (CCW) at a constant rate of 0.5°/s. Moment 
and angle data were recorded for subsequent analysis with 
a custom script in MATLAB (R2008, The MathWorks, 
Natick, MA, USA) to determine the removal torque (RT: 
Nmm) and interfacial stiffness (Nmm/°) values.
Statistical analysis
The data are presented as mean values plus/minus standard 
deviation. Data distribution was tested by the Kolmogorov-
Smirnov-Test. Variance analysis of all groups by analysis 
of variance (ANOVA) and following Bonferoni adjusted 
multiple comparisons of mean values were performed. 
Differences in variance between measurement parameters 
were analysed by Pearson correlation coefficient. The level 
of significance was set at α = 0.05 in all statistical tests. 
Statistical analysis was performed by SPSS for Windows® 
19 (SPSS, Chicago, IL, USA).
Results
Animals
Six animals died during anaesthesia and one animal was 
euthanised due to wound healing complications. Seven 
histological samples were not included in the histological 
analysis due to bicortical insertion.
Fig. 2. MicroCT images exemplifying the difference in bone template in the proximal tibia between oestrogen 
competent (a) and oestrogen deprived (b) animals four weeks post-implantation.
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Bone-Implant Contact (BIC)
BIC was comparable between the oestrogen competent 
groups having received the reference implant or the implant 
with the conditioned surface both at two and four weeks 
according to microCT and histomorphometric readouts 
(Tables 2 and 3). The two corresponding OVX groups 
were also comparable at both time points. However, they 
had dramatically reduced BIC compared to intact animals. 
Structurally these findings correlated to a poor bone 
template in the long-term oestrogen deprived animals: both 
in the region adjacent to the implant and the neighbouring 
region (Tables 2 and 3, Fig. 2).
 Two weeks post-implantation neither collagen/
chondroitin sulphate nor zoledronic acid coating had any 
impact on BIC compared to OVX controls (Tables 2 and 
3), while statin coating improved BIC. After four weeks 
however, no effect related to latter was detectable. At this 
time point zoledronic acid coated implants displayed a 
higher BIC than controls, while the BIC of implants having 
received collagen/chondroitin sulphate coating remained 
comparable to controls (Tables 2 and 3). Consequently, all 
oestrogen-deprived osteopenic animals displayed lower 
BIC than oestrogen-competent animals with the exception 
of those having received zoledronic acid coated implants. 
In general BIC was lower in OVX rats after four weeks 
compared to two weeks, with the exception of the group 
with zoledronic acid coated implants which displayed a 
higher BIC at the later time point (Tables 2 and 3).
Cancellous bone mass
MicroCT analyses demonstrated dramatically reduced 
cancellous bone volume (BV/TV) and cancellous bone-
mineral density (BMD) in all oestrogen-depleted animals 
two and four weeks post-implantation compared to 
oestrogen-competent rats irrespective of implant surface 
treatment (Table 2). However, BV/TV was higher in the 
group having received zoledronic acid coated implants 
compared to all other OVX groups after four weeks (Table 
2). BMD values showed a similar pattern. Analogous to 
BIC, the amount of cancellous bone decreased in OVX 
rats between two and four weeks with the exception of the 
group having received zoledronic acid coated implants, 
while it remained stable in intact animals (Table 2).
 Histomorphometric results (Table 3) confirmed the 
microCT findings. Oestrogen deprived rats had at both time 
points irrespective of implant surface treatment lower bone 
area (BA) values adjacent to the implant. Consistently BA 
was higher in the group having received zoledronic acid 
coated implants compared to all other OVX groups after 
four weeks (Table 3). Moreover, in alignment with the 
microCT results BA adjacent to the implant decreased in 
OVX rats between two and four weeks with the exception 
of the group having received zoledronic acid coated 
implants, but was stable in intact animals (Table 3). The 
distant BA neighbouring the tissue area adjacent to the 
implant showed a slightly different pattern, insofar as all 
OVX groups displayed at both time points reduced BA 
compared to non-OVX animals including the zoledronic 
acid coated implant group with one exception. At the 
two-week time point, the group which had been exposed 
to statin coated implants displayed in this region a higher 
BA (Table 3). However, by four weeks this effect was 
not detectable anymore and BA was comparable between 
OVX groups, which was somewhat lower, though not 
Group Surface
Healing time BIC cancellous bone BA adjacent BA distant
[weeks] n [%] SD [%] SD [%] SD
non- 
OVX
reference 2 7  52.9# 14.6 47.1# 19.9 28.0# 13.6
reference 4 6  66.5# 11.5 42.6# 11.8 29.3# 11.2
conditioned 2 7  55.3# 13.6 43.1# 12.7 28.3#  9.7
conditioned 4 7  51.1# 12.0 43.0# 13.5 30.6# 10.0
OVX
reference 2 8  24.1*  8.6 16.4* 9.0   8.7*  6.7
reference 4 7  10.7*  9.3   4.5* 4.2   6.0*  5.9
conditioned 2 7 35.2 18.0 16.0* 6.5 10.2*  5.8
conditioned 4 6  19.3*  6.8   6.3* 3.7  8.6*  4.6
collagen/CS 2 8 31.5 12.2 18.4* 7.5 10.0*  6.6
collagen/CS 4 7  14.2*  8.0   5.6* 4.2   5.7*  2.7
simvastatin 2 8  38.9 19.8 28.6* 9.9 17.7  4.7
simvastatin 4 6   25.6*  4.6   9.3* 3.9   6.0*  3.4
zoledronic 
acid 2 7   18.1*  8.4 23.1* 6.2   9.7*  7.0
zoledronic 
acid 4 7    43.2*# 17.8 23.8*# 8.6   7.3*  5.4
Table 3. Results of histomorphometry at two and four weeks.
Significantly different (p ≤ 0.05) compared to reference in non- OVX (*) or OVX (#) rats at the same time point; 
equal number of animals (n) for all parameters.
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significantly so  (with the exception of the statin exposed 
group), than at two weeks. Overall, BA was higher in the 
area adjacent to the implant than in the neighbouring distant 
region (Table 3, Fig. 3).
Fluorochrome marker uptake
Calcein labels were readily detectable and more 
pronounced two weeks post-implantation. In addition to 
the incorporation of fluorochrome labels in the unaffected 
secondary spongiosa and endosteum at sites of bone 
formation and mineralisation related to normal bone 
turnover, a high level of intensive calcein labelling was 
detectable in peri-implant tissues up to 1 mm distance from 
the implant surface. This appeared most pronounced for the 
collagen/chondroitin sulphate and statin coated surfaces. 
By four weeks peri-implant label uptake was low. Alizarin, 
Fig. 3. Histology (Masson-Goldner staining): After 2 weeks, reference implant surfaces in the tibiae of oestrogen 
competent rats displayed homogenous bone formation within implant threads (a). This zone was remodelled by 4 
weeks and the implant integrated in the regular trabecular bone structure (b). The tibiae of OVX rats with zoledronic 
acid coated implants; also some trabecular structures with partial implant contact were visible after 2 weeks (c), 
which were also observed after 4 weeks within implant threads (d).
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which had been applied earlier than calcein, was generally 
rarely visible in the peri-implant area at either time point. A 
marked qualitative difference in peri-implant fluorochrome 
marker uptake was not noticed between OVX rats and 
intact controls. (Fig. 4).
Biomechanical properties
Removal torque was lower in all oestrogen-deprived groups 
compared to oestrogen-competent groups (Table 4) at both 
time points. None of the implant surface coatings had any 
significant impact on removal torque at either time point 
(Table 4). Removal torque was higher at four weeks in all 
groups compared to two weeks, reaching significance in the 
intact groups and the OVX groups exposed to zoledronic 
acid or collagen/chondroitin coated implants (data not 
shown). Stiffness was largely comparable between groups 
irrespective of oestrogen status and implant surface 
treatment (Table 4). Only the OVX group having received 
the reference implant displayed decreased stiffness at the 
two-week time point. Generally, stiffness was somewhat 
higher at four weeks in all groups reaching significance 
in most with the exception of the intact group with the 
conditioned implant surface and the OVX group with the 
statin coated surface (data not shown).
Correlation between assessed parameters
Consistent with the above-described findings the 
correlation analysis showed a significant correlation 
between various parameters two and four weeks post-
implantation: BIC by microCT and histomorphometry 
showed a significant correlation to adjacent and distant BA 
by histomorphometry, BV/TV and BMD by microCT and 
Fig. 4. Fluorescence microscopy: reference implants in 
oestrogen competent rats (a, b), and OVX rats (e, f) two (a, 
e) and four (b, f) weeks post-surgery; conditioned implants 
in oestrogen competent (c, d) and OVX (g, h) rats two (c, g) 
and four (d, h) weeks post-surgery; collagen / chondroitin 
sulphate coated implants in OVX rats two (i) and four (j) 
weeks post-surgery; simvastatin coated implant in OVX 
rats two (k) and four (l) weeks post-surgery, zoledronic 
acid coated implant in OVX rats two (m) and four (n) 
weeks post-surgery.
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removal torque. The results of the stiffness test correlated 
to removal torque at both time points and 2 weeks post-
implantation to BV/TV and BMD (Table 5).
Discussion
Several previous studies have analysed the impact of 
conditioning or drug coating of implant surfaces in animal 
models of osseointegration (Buser et al., 2004; Rammelt et 
al., 2007; Wermelin et al., 2008b). Increased peri-implant 
bone formation and improved biomechanical characteristics 
have been demonstrated for such surface treatments in 
some cases. An improvement of osseointegration would 
be especially beneficial in compromised osseous situations 
such as osteoporosis (Bernhardt et al., 2005), which is 
characterised by a systemic deterioration of bone mass 
and microarchitecture (Rachner et al., 2011). Studies 
analysing implant osseointegration in osteoporotic patients 
yielded differential results. Whereas some studies report 
increased implant loss rates for osteoporotic patients (Moy 
et al., 2005; Alsaadi et al., 2007), others did not observe 
increased implant loss rates for these patients (Dvorak 
et al., 2011). A systematic review describes the level of 
evidence for studies on this matter as multiple case-control 
studies (Bornstein et al., 2009). In the present study, we 
analysed the osseointegration of a number of different 
conditioned or coated implants. Some of these surfaces 
have previously been described to display increased 
osseointegration in animal models under compromised 
osteoporotic conditions. We utilised aged rats, which 
were oestrogen-deprived by ovariectomy, as a standard 
model for the simulation of post-menopausal osteoporosis 
(Thompson et al., 1995). Following ovariectomy, bone 
resorption exceeds bone formation, increasing bone 
turnover and inducing rapid cancellous bone loss resulting 
in a severely rarefied trabecular network within three 
months (Jee and Yao, 2001). We placed the implants 
three months post-ovariectomy into the proximal tibia 
metaphysis as a well characterised skeletal site for sex-
hormone deprival induced bone loss. As expected, both 
microCT and histological evaluation confirmed a severely 
compromised cancellous bone network in the proximal 
tibia of those aged animals.
 The first implant modification for improvement 
of implant osseointegration we tested was surface 
conditioning as a means to modify the physicochemical 
characteristics of an implant. Histomorphometric and 
micro-CT measurements of BIC and bone volume served 
to quantify peri-implant bone formation. The correlation of 
histological and micro-computed tomographic data for the 
analysis of BIC and bone volume has been analysed in an 
earlier study applying synchrotron radiation (Bernhardt et 
al., 2012). The conditioning by hydroxide ions influences 
surface charge, hydrophilicity and the homogeneity of 
the initial protein layer (Tugulu et al., 2010). Various 
animal studies utilising non-osteoporotic conditions 
have analysed mechanics and histomorphometry of such 
conditioned implants, and demonstrated increased bone 
formation and removal torque values indicating improved 
osseointegration (Ferguson et al., 2006; Calvo-Guirado et 
al., 2010; Stadlinger et al., 2012). However, in our setting, 
we observed – neither in osteoporotic oestrogen deprived 
nor in non-osteoporotic oestrogen-competent animals – 
an increase of bone-implant contact or an improvement 
of biomechanical properties in comparison to reference 
Table 4. Results of mechanical testing at two and four weeks.
Group Surface
Healing time Removal torque Stiffness
[weeks] n [Nmm] SD [Nmm/°] SD
non- 
OVX
reference 2 8   57.0# 13.9  29.5# 2.5
reference 4 8   85.7# 21.9 31.3 3.4
conditioned 2 8   56.0# 18.6  29.5# 3.6
conditioned 4 8   94.7# 20.9 35.3 4.4
OVX
reference 2 8   30.5*   9.6   19.2* 10.1
reference 4 8   41.5* 15.5 33.3 8.2
conditioned 2 8 36.7 12.5   26.1* 7.2
conditioned 4 8   43.6*   7.5 33.7 5.6
collagen/CS 2 8  37.4 13.0 26.5 3.9
collagen/CS 4 8   50.4*   9.8 36.7 6.9
simvastatin 2 8   32.0* 12.6 22.1 7.1
simavstatin 4 8   44.2* 13.6 28.5 7.1
zoledronic acid 2 8   29.8* 10.5 24.1 6.0
zoledronic acid 4 8   52.9* 17.0 31.0 4.3
Significantly different (p ≤ 0.05) compared to reference in non- OVX (*) or OVX (#) rats at the same time point;
equal number of animals (n) for both parameters.
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surfaces. This difference might relate to a diminishing 
pool of osteoprogenitor cells in those ageing animals (Pei 
et al., 2003). Next, we tested whether implant coating 
with components of the bone extracellular matrix (ECM) 
would stimulate bone osseointegration in our compromised 
setting (Stadlinger et al., 2009a). Collagen type I is the 
main structural component of the bone organic ECM and 
has been previously demonstrated to favour the adhesion 
of osteoblastic cells (Becker et al., 2002). In addition, the 
application of glycosaminoglycans such as chondroitin 
sulphate (CS) influences the adhesion, proliferation and 
differentiation of osteoblasts (Bierbaum et al., 2006; 
Douglas et al., 2007). Accordingly, the suitability of 
collagen/CS coated implant surfaces has been assessed 
in various in vitro and in vivo studies. In minipigs, 
collagen/CS coated implants showed improved implant 
osseointegration, compared to pure collagen coatings 
(Stadlinger et al., 2008). Such coated implants, displayed 
in mandibular and maxillary bone, increased BIC compared 
to sandblasted, acid-etched implants 4 weeks post-
implantation (Stadlinger et al., 2009a; Stadlinger et al., 
2011). In addition, Rammelt et al. examined collagen/CS 
coated intramedullary nails in tibiae of 90 days old intact 
male rats and showed increased bone formation and bone 
Table 5. Inter-group-correlation analysis. Pearson correlation coefficient and two-tailed p values (in brackets) are 
shown for each parameter and time point.
*  The correlation was statistically significant at a level of 0.05 (two tailed). ** The correlation was statistically 
significant at a level of 0.01 (two tailed).
Time Parameter
BIC
(Hist.)
BA 
adjacent
BA 
distant
Removal 
torque Stiffness
BIC
(MicroCT) BV/TV BMD
2 
weeks
 
BIC (Hist.) 1 0.685** 0.638** 0.382** 0.224 0.538** 0.476** 0.473** 
(0.000) (0.000) (0.005) (0.111)  (0.000)  (0.001)  (0.001)
BA adjacent 0.685** 1 0.910** 0.406** 0.153 0.617** 0.617** 0.616** 
(0.000) (0.000) (0.003) (0.278)  (0.000)  (0.000)  (0.000)
BA distant 0.638** 0.910** 1 0.318* 0.132 0.687** 0.652** 0.655** 
(0.000) (0.000) (0.021) (0.351)  (0.000)  (0.000)  (0.000)
Removal torque 0.382** 0.406** 0.318* 1 0.601** 0.490** 0.521** 0.507** 
(0.005) (0.003) (0.021) (0.000)  (0.001)  (0.000)  (0.000)
Stiffness 0.224 0.153 0.132 0.601** 1 0.275 0.353* 0.294* 
(0.111) (0.278) (0.351) (0.000) (0.067)  (0.012) (0.036)
BIC (MicroCT) 0.538** 0.617** 0.687** 0.490** 0.275 1 0.962** 0.973** 
(0.000) (0.000) (0.000) (0.001) (0.067)  (0.000)  (0.000)
BV/TV 0.476** 0.617** 0.652** 0.521** 0.353* 0.962** 1 0.985**
(0.001) (0.000) (0.000) (0.000) (0.012)  (0.000)  (0.000)
BMD 0.473** 0.616** 0.655** 0.507** 0.294* 0.973** 0.985** 1
(0.001) (0.000) (0.000) (0.000) (0.036)  (0.000)  (0.000)
4 
weeks
 
BIC (Hist.) 1 0.847** 0.700** 0.570** -0.056 0.807** 0.764** 0.786**
(0.000) (0.000) (0.000) (0.714)  (0.000)  (0.000)  (0.000)
BA adjacent 0.847** 1 0.893** 0.615** 0.029 0.867** 0.817** 0.844** 
(0.000) (0.000) (0.000) (0.849)  (0.000)  (0.000)  (0.000)
BA distant 0.700** 0.893** 1 0.600** 0.094 0.764** 0.765** 0.774** 
(0.000) (0.000) (0.000) (0.536)  (0.000)  (0.000)  (0.000)
Removal torque 0.570** 0.615** 0.600** 1 0.316* 0.614** 0.695** 0.703** 
(0.000) (0.000) (0.000) (0.018)  (0.000)  (0.000)  (0.000)
Stiffness -0.056 0.029 0.094 0.316* 1 -0.085 -0.079 -0.070
(0.714) (0.849) (0.536) (0.018) (0.568) (0.584) (0.630)
BIC (MicroCT) 0.807** 0.867** 0.764** 0.614** -0.085 1 0.970** 0.978** 
(0.000) (0.000) (0.000) (0.000) (0.568)  (0.000)  (0.000)
BV/TV 0.764** 0.817** 0.765** 0.695** -0.079 0.970** 1 0.992** 
(0.000) (0.000) (0.000) (0.000) (0.584)  (0.000)  (0.000)
BMD 0.786** 0.844** 0.774** 0.703** -0.070 0.978** 0.992** 1
 (0.000) (0.000) (0.000) (0.000) (0.630)  (0.000)  (0.000)  
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remodelling in comparison to uncoated surfaces (Rammelt 
et al., 2006). In our study in older female rats, collagen/
CS coated surfaces did not show significant differences in 
mechanics and peri-implant bone formation in comparison 
to uncoated surfaces. Increased values in mechanical tests 
did not reach a level of significance. This is somewhat 
unexpected as the promising results obtained previously 
in large animal models suggested that a pronounced 
positive effect might also be detectable under osteoporotic 
conditions. Yet, our results indicate that in a setting of 
severely reduced bony template and a presumably reduced 
osteoblastic precursor pool such surface coatings cannot 
exert their beneficial effect.
 We also tested a principle that has been previously 
suggested to impact bone formation by stimulating bone 
morphogenetic proteins (BMPs). It is well established 
that the differentiation of osteoblastic cells is increased 
by BMPs (Mundy et al., 1999) and that this is relevant to 
implant osseointegration. Different studies have suggested 
that BMP expression can be stimulated by statins (Oxlund 
et al., 2001; Skoglund et al., 2002). Clinically, statins are 
administered to decrease high cholesterol levels through 
inhibition of the enzyme HMG-CoA reductase which 
is involved in the cholesterol synthesis. Induction of an 
osteoanabolic effect occurs only at higher dosages than 
required for cholesterol inhibition (Moriyama et al., 
2010). In addition, a putative inhibition of osteoclast 
activation has been proposed (Moriyama et al., 2010). 
Statins have been applied in various animal models of 
osseointegration and improved implant integration rates 
in non-compromised (Ayukawa et al., 2010; Moriyama 
et al., 2010) and osteoporotic animal models (Du et al., 
2009) have been reported. Local application of fluvastatin 
increased peri-implant bone formation in the tibial bone 
of oestrogen competent growing ten-week-old female 
rats, (Moriyama et al., 2010). In addition, systemic high 
dose treatment improved peri-implant bone deposition 
in the implant carrying tibial medullar cavity of intact 
skeletally mature 30-week-old female rats (Ayukawa et 
al., 2010). Moreover, systemic application of simvastatin 
to 5-month-old rats, which had been ovariectomised 
two months prior to implant placement, also enhanced 
osseointegration (Du et al., 2009). We used in our study 
older animals than any previous study and placed implants 
after a more extended oestrogen deprival induced bone loss 
period, while the examined implant healing intervals were 
comparable to other studies. In comparison to Du et al. 
(2009), cancellous bone loss was far more pronounced in 
our study. In addition, implant insertion was in the present 
study mono-cortical while Du et al. performed bi-cortical 
insertion. Since the successful local application of statins 
has been demonstrated to depend on an effective drug 
delivery system, like chitosan, PGA (Moriyama et al., 
2010) or methylcellulose gels (Thylin et al., 2002), we 
have utilised chitosan in the present study. In accordance 
with previous studies, we observed a transient increase 
in BIC and the amount of peri-implant bone in the group 
that had received statin coated implants. Consistently, 
fluorochrome marker uptake appeared in the peri-implant 
area elevated two weeks post-implantation compared to 
other surfaces. However, these changes did not translate 
into improved biomechanical readouts and at the later 
time-point no impact of the statin coating was detectable 
any more. Since we consider our animal model to more 
faithfully mimic severely compromised osteoporotic 
settings, we conclude that the ability of locally released 
statins to improve osseointegration under such conditions 
is limited.
 Finally, to complete the spectrum of implant surface 
modifications that are known to impact bone metabolism 
and thus may impact osseointegration we tested an 
anti-resorptive principle. Bisphosphonates are potent 
anti-resorptive drugs that primarily target osteoclasts 
(Abtahi et al., 2010). Clinically, bisphosphonates are 
administered intravenously in patients suffering from 
bone metastasis of malignant tumours. Lower doses 
of various bisphosphonates are applied by infrequent 
oral or intravenous injection for various bone fragility 
conditions including osteoporosis. In addition to systemic 
treatments, local release from implant surfaces has already 
been tested previously in preclinical settings (Gao et al., 
2009; Wermelin et al., 2008b). Zoledronic acid is a potent 
bisphosphonate with a high affinity to mineralised bone 
(Li and Davis, 2003). In the present study zoledronic 
acid coated surfaces were the only implants that lead to a 
significant increase in BIC from two to four weeks. The 
animals that had received those implants displayed an 
increase in the amount of bone surrounding the implant 
at the end of the study. Consistently, maintenance of a 
higher amount of fluorochrome labelled peri-implant 
bone was visible at the end of the study compared to other 
groups. Since bone resorption and bone formation are 
uncoupled during a repair process like osseointegration, 
bone formation can commence despite the presence of the 
anti-resorptive bisphosphonate opposed to situations in 
which bone resorption and bone formation are coupled such 
as normal adult bone remodelling (Baron and Kneissel, 
2013). However, the apparently increased fluorochrome 
marker uptake does not necessarily reflect increased bone 
formation compared to the other groups, but could simply 
reflect the maintenance of the newly formed bone by anti-
resorptive action, while this bone was rapidly removed 
in the other groups in the absence of such a principle. 
As mentioned above, various previous studies analysed 
the application of bisphosphonates on osseointegration 
in animals. Consistent with our results, improvement 
of the amount of peri-implant bone formation was also 
detected in OVX rats after 8 weeks (Gao et al., 2009). Of 
note compared to our study, Gao et al. operated younger 
rats, which however also underwent implant placement 
in the tibial medullar cavity three months post-OVX. 
Three months post-implantation, bone area and BIC were 
found to be doubled in animals carrying implants with 
bisphosphonate coatings on a hydroxyapatite implant 
surface layer (Gao et al., 2009). Our findings are overall 
consistent with other studies, showing increased implant 
fixations for bisphosphonate coatings using different 
carriers and displaying different drug release kinetics 
(Andersson et al., 2010; Peter et al., 2006), though 
involved. Wermelin et al. analysed the surface release of 
bisphosphonates, showing that one third of the coating was 
released within 4 weeks (Wermelin et al., 2008a). Gao et 
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al. demonstrated zoledronic acid coating up to 21 days 
after implantation (Gao et al., 2009). In the present study, 
analyses of the release kinetics of statin and zoledronic acid 
coatings revealed a surface release restricted to 7-13 days, 
indicating that this local relatively short-term release was 
sufficient to induce longer-term effects as detected up to 
one month. Though the bisphosphonate coating emerged 
in this setting of severely osteoporotic and compromised 
bone as the most promising principle, safety aspects have 
to be considered. Clinically, the intra-oral application 
of bisphosphonates needs to address the aspect of oral 
necrosis of the jaw (ONJ). The ONJ has been described in 
various studies for the systemic application of high dose 
bisphosphonates in cancer patients (Marx, 2003; Ruggiero 
et al., 2009). Abtahi et al. addressed this question and 
describes that no animal study observed to date necrotic 
bone around bisphosphonate coated implants (Abtahi et 
al., 2010). They further examined the infiltration depth 
of surface bound bisphosphonates into the peri-implant 
bone, measuring a maximum distance of less than 1 mm 
(Abtahi et al., 2010; Wermelin et al., 2008b). A translation 
of the mentioned animal studies to the human situation 
is limited by the fact that implants healed submerged. A 
loaded dental implant in humans, however, is exposed to 
the oral cavity and oral bacteria. A further consideration 
is long-term implant stability, which requires continuous 
bone remodelling in order to preserve osseointegration 
(Roberts et al., 1992). To date, first results in humans 
receiving zoledronic acid coated implants indicate 
increased stability after 6 months of submerged healing 
(Abtahi et al., 2012). Further investigations are required 
to assess how implants from which bisphosphonates have 
been released respond to remodelling processes following 
implant loading. Limiting release of the drug to a shorter 
time window, like in the present study, may be one way to 
limit the amount of peri-implant bone that is exposed to 
the anti-resorptive principle, allowing hence for a faster 
recovery of remodelling based bone turnover.
 In summary, the present study assessed the impact 
of implant surface modifications, which have resulted 
previously in improved osseointegration in preclinical 
settings, in an animal model of severe osteoporosis. In this 
setting, most modifications did not yield an appreciable 
improvement, though simvastatin coating had a transient 
positive impact on the amount of peri-implant bone and 
the amount of bone-implant contact. Only zoledronic acid 
coating improved osseointegration at the end of the study, 
suggesting that such coatings may be of interest in the 
settings of severely compromised bone template. Further 
studies are, however, required to demonstrate the long-term 
success of such coated implants.
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Discussion with Reviewers
Reviewer I: Which animal model would you prefer if you 
would repeat the experiment in a large animal model? What 
differences to the presented approach would you expect? 
Which size of implants would you choose? The larger size 
of implants would lead to an increased load of bioactive 
factors. Could this improve results?
Authors: A possible large animal model would be 
minipigs. Ovarectomy-induced oestrogen deficiency 
has been shown to manifest stronger in primiparous as 
compared to nulliparous minipigs (Scholz-Ahrens et 
al., 1996, additional reference). Supplementary calcium 
deficient diet and glucocorticoid application, however, 
has been able to induce osteopenia in nulliparous (Scholz-
Ahrens et al., 2007, additional reference). The advantage 
would be the placement of clinically applied implants. 
Larger implants of course would offer the opportunity to 
increase the load of bioactive factors. However, the effect 
of higher drug doses on osseointegration has to be carefully 
tested, Based on previous reports in the literature (Peter 
et al., 2006, text reference), there seems to be an optimal 
dosage, especially for the use of bisphosphonates.
Reviewer II: The aim of this work was to assess the impact 
of surface modifications on implants osseointegration 
and anchorage in a severely osteoporotic rat model. 
The study suggests that most surface modifications that 
have a positive effect in healthy bone may not have it in 
osteoporotic bone anymore. It is surprising that an effect 
is seen in bone-implant contact and bone density around 
implants, but this doesn’t translate into a mechanical 
benefit. Could the authors comment on this discrepancy?
Authors: Although the constituents of bone are present (as 
evidenced by the mineral content and the bone-implant-
contact), the development of these constituents into a 
fully-functional and integrated composite is delayed or 
compromised in osteoporotic bone. This may be seen as 
analogous to the difference between immature woven bone 
and fully remodelled, functional bone.
Reviewer II: What was the rationale to choose removal 
tests rather than pull-out or shear resistance tests? Have the 
authors considered FE modelling to numerically estimate 
pull-out strength from the microCT data?
Authors: Removal torque testing of threaded implants is 
a reliable method for determining the influence of surface 
treatments on osseointegration, which is less sensitive to 
testing artefact. Push-out, pull-out or shear tests are either 
subject to end effects with axial loading into the bone, 
require a substantially-sized implant to facilitate pull-out 
testing, or require specimen sectioning to perform shear 
tests. Any cutting of the implant/bone interface, e.g. to 
produce a standard push-out or shear test specimen, brings 
with it the risk of damaging the bone-implant interface. In 
the rat model, the chosen implant and torque test have the 
advantage of providing a low-profile implant head, which 
requires no further specimen preparation before performing 
the biomechanical test. The entire bone can be mounted for 
testing and the implant must not be strongly clamped in the 
testing machine to perform the measurement; it requires 
only a form-fit adapter and therefore no mechanical load 
is placed on the implant prior to testing.
 FEA based on microCT has been shown to be inaccurate 
in the prediction of interfacial mechanical behaviour, as 
the true nature of the interface (bonded or non-bonded) 
cannot be determined a priori and non-bonded interfaces 
are computationally expensive. Therefore, FE models 
based on microCT rarely provide an accurate prediction 
of interfacial stiffness or strength.
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Reviewer III: If (especially a straight) implant is loaded 
with a specific coating, how can the authors be sure not 
to detach the coating while installing the implant screw, 
leading to a very high concentration in the upper part and 
only a very low concentration in the lower? The implant 
thread design looks very aggressive, would you expect 
the same results even with an implant with more shallow 
threads, leaving less space between the bone and the 
implant?
Authors: The selected implant thread design serves to 
enable primary implant stability in this reduced bone 
quality. In this animal model, more shallow threads may 
cause micromotion and thus impede a possible conclusion 
on surface coating effects. Due to the low concentration 
of agents, very thin layers below 5 µm thickness were 
produced. The applied coating method produces relatively 
homogenous layers that strongly attach to metal surfaces. 
Certainly mechanical friction during implant insertion 
will influence the coating especially in the tip areas. 
However, due to the prior implant surface modification 
by sandblasting and acid etching, the coating components 
also penetrate into surface pores, thus being secured from 
friction during implant placement. The demonstrated 
effects of coating agents demonstrate sufficient remaining 
agent on the surface.
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